Meet Kathrin Jansen, the woman leading Pfizer’s COVID-19 vaccine effort

{ object.primary_image.title }}

The rock star scientist has a track record of producing difficult vaccines against the odds. Pfizer has made an incredible announcement: Its COVID-19 vaccine looks like it is 90% effective at preventing the disease inside its clinical trial. It’s a remarkable number: In the last 10 years, flu vaccine efficacy rates have wobbled between 19% and 60%. Outside scientists are now keen to see the full data in order to validate the findings. In the meantime, many are rejoicing at the prospect of a better tool for fighting COVID-19. Read Full Story

Read Full Article on Fast Company

Pfizer’s CEO: 3 key decisions helped it develop a COVID-19 vaccine in record time

{ object.primary_image.title }}

In an interview with Fast Company Editor-in-Chief Stephanie Mehta, Pfizer CEO Albert Bourla credited quick decision-making, trust in science, and artificial intelligence software for his company’s ability to create a highly effective COVID-19 vaccine in record time. Last year, Pfizer was one of several pharmaceutical companies to take on an incredible challenge: make a life-saving vaccine in a fraction of the time it usually takes to do so. Over the course of 2020, Pfizer and others tested vaccine candidates as hundreds of thousands of people died from COVID-19. Pfizer’s success at creating a vaccine with 95% efficacy in record time has landed it, along with its partner BioNTech and fellow vaccine maker Moderna, atop Fast Company ‘s Most Innovative Companies list for 2021 . Read Full Story

More

FDA advisory council signals support for Pfizer’s COVID-19 vaccine

{ object.primary_image.title }}

Pfizer’s vaccine now has the blessing of the FDA’s advisory council, an important step in moving toward approval. A panel of vaccine and infectious disease experts advising the Food and Drug Administration voted to approve Pfizer’s COVID-19 vaccine for anyone 16 years and above. The decision is likely to influence whether the FDA moves to approve the vaccine under emergency use authorization. Read Full Story

More

Pfizer unveils its first major logo redesign in 70 years

{ object.primary_image.title }}

A new brand identity aims to embody the pharma giant’s shift from pills like Advil and Viagra to the science of vaccines. Pharmaceutical giant Pfizer has unveiled its most significant brand refresh in about 70 years. It includes a new logo, dropping the blue pill shape for a double helix-inspired mark, which conjures the science that gave rise to the company’s COVID-19 vaccine. It’s the final step in a shift the company began in 2019, moving from a diverse collection of consumer brands to a more science-driven agenda creating prescription drugs and vaccines. Read Full Story

More

How to distribute the COVID-19 vaccine: Lessons from Amazon and Walmart

{ object.primary_image.title }}

Supply-chain ideas practiced by Amazon and Walmart can help reduce waste and minimize shortages of COVID-19 vaccines. The initial rollout of Pfizer’s COVID-19 vaccine has begun, and vaccines are shipping across the U.S. Demand for COVID-19 vaccines will outpace supply for the foreseeable future. Yet experts have warned that a substantial proportion of these highly perishable vaccines could go to waste if they are not being used before they expire. Read Full Story

More

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing

{ object.primary_image.title }}

Albert Bourla talks about his employees’ effort to develop a COVID-19 vaccine in record time, Pfizer’s friendly rivalry with Moderna, and what’s next for the pharmaceutical giant. To mark the year since the World Health Organization declared COVID-19 a global pandemic, Pfizer CEO Albert Bourla penned an open letter , reflecting on a year of loss and discovery. He praised his employees and the pharmaceutical industry for its ability to innovate and collaborate. (Pfizer and Germany’s BioNTech received the first authorization for a COVID-19 vaccine in December 2020.) Read Full Story

More

Pfizer COVID-19 vaccine: The timeline now that FDA emergency use has been requested

{ object.primary_image.title }}

However, even if the EUA is granted, the chances of the average American receiving Pfizer’s COVID-19 vaccine in 2020 is slim. Just days after announcing their COVID-19 vaccine has an efficacy rating of at least 95% , Pfizer has announced that they plan to ask the Food and Drug Administration for emergency use authorization (EUA) today, reports CNBC. That request is the first step in getting the vaccine approved for use among the general public on a shortened timeline. Read Full Story

More

Oxford COVID-19 vaccine: Not as effective, but better than other vaccines in two big ways

{ object.primary_image.title }}

The effacacy of the Oxford vaccine is relatively low compared to Moderna’s and Pfizer’s—but it has two major advantages over its competitors. Another week and more good news in the fight against COVID-19. For the third week in a row, a successful COVID-19 has been announced—this time from researchers at Oxford University in the United Kingdom, reports the BBC. The Oxford vaccine has been one of the longest in the making—work began almost 10 months ago. However, the Oxford vaccine has a major drawback versus the American vaccines, but it also has two major advantages. Here’s what you need to know. Read Full Story

More

How Pfizer’s COVID-19 vaccine works: mRNA

{ object.primary_image.title }}

The vaccine uses a new, innovative form of biotechnology to make the body produce antibodies to protect itself against the virus. In January, as cases of the new, mysterious coronavirus were growing in China—but two months before the World Health Organization declared the disease a pandemic—a handful of small biotech companies began scrambling to develop vaccines using an as-yet-unproven technology platform that relies on something called messenger RNA, usually shortened to mRNA. One was Moderna, which completed its first clinical batch of a vaccine by February and launched human trials in March, faster than any other vaccine in history. Another was BioNTech, a German company that later partnered with Pfizer to make a vaccine that the companies now say has been proven highly successful in trials, reaching 90% effectiveness. Read Full Story

More

Pfizer’s COVID-19 vaccine: 6 things to know

{ object.primary_image.title }}

Yes, it’s very good news—yet it’s important to keep hopes and expectations in check. Nothing is certain yet. There’s some massive news out about COVID-19—and it’s good for a change. Pfizer and BioNTech’s vaccine is reportedly successful in preventing over 90% of infections according to early data from its phase 3 study , says STAT News. Needless to say, if the data holds as the study continues, this vaccine could be the thing that turns the tide of the COVID-19 pandemic in humanity’s favor. Read Full Story

More

Subscribe to our newsletter

Join our newsletter and never miss out trending marketing news.

HitcountVariables(pk=11215, ajax_url='/api/hit/ajax/', hits='7')